The favorable outcome is consistent with a large retrospective report of patients with AML harboring mutations in spliceosome genes treated with lower-intensity regimens containing venetoclax.21 This case also supports synergy of BCL2 inhibition with venetoclax and BCR::ABL1 inhibition in myeloid malignancies.13 Given the low number of patients with TAR diagnosed with AML, it is difficult to determine if this approach can be extrapolated to other patients with TAR, warranting future clinical studies. This evidence concerns the gene BCL2 and acute myeloid leukemia.